IDEAS home Printed from https://ideas.repec.org/a/eur/ejmnjr/39.html
   My bibliography  Save this article

Effects of Adverse Drug Reactions and Adverse Drug Events in Hospital Admission Rates and Re-Hospitalization of Patients

Author

Listed:
  • Festina Balidemaj

    (Lunds Universitet Medicinska Fakulteten,Lund, SwedenNorthwestern Health Sciences University, Minneapolis, Minnesota, USA)

Abstract

Background: ADRs and ADEs have a great potential to hospitalize and/or re-hospitalize patients. According to McDonnell and Jacobs, one ADR or ADE could lead a patient to a hospital length of stay of an average of 6.1 days. This can lead to lost days of work, a longer recovery time and even economic implications. Methods: A thorough evaluation of the relevant extracted literature has been analyzed thoroughly in order to find out how ADRs and ADEs impact the levels of hospitalization and re-hospitalization of patients and whether strategies, such as reporting systems, can aide in decreasing their overall occurrence. Results: As the level of hospital admissions/re-hospitalizations due to ADRs and ADEs depends on different factors, such as age and location, the data is separated in the following categories: pediatric population, general adult populations and geriatric population. Where data were available, location has been specified within each category as well. Conclusion: ADR and ADE-related hospital admission and readmission rates are age-group related, elderly being at the highest risk. However, these rates are not dependent on whether a country is developed or developing. Also, there are strategies that can be utilized by healthcare providers in order to decrease these rates in the future, such as to provide medication reviews and follow-ups.

Suggested Citation

  • Festina Balidemaj, 2021. "Effects of Adverse Drug Reactions and Adverse Drug Events in Hospital Admission Rates and Re-Hospitalization of Patients," European Journal of Medicine and Natural Scinces Articles, Revistia Research and Publishing, vol. 4, January -.
    • Handle: RePEc:eur:ejmnjr:39
    DOI: 10.26417/337hsv20h
    as

    Download full text from publisher

    File URL: https://revistia.com/index.php/ejmn/article/view/5046
    Download Restriction: no
    File URL: https://revistia.com/files/articles/ejmn_v4_i1_21/Balidemaj3.pdf
    Download Restriction: no
    File URL: https://libkey.io/10.26417/337hsv20h?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eur:ejmnjr:39. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Revistia Research and Publishing (email available below). General contact details of provider: https://revistia.com/index.php/ejmn .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.